| 查看: 274 | 回复: 2 | |||||||||||||
[交流]
大临床总监
|
|||||||||||||
JOB SUMMARY: Innovent Biologics is currently seeking an experienced and energetic individual to oversee our clinical trials as Executive Director or Vice President of Clinical Development. ESSENTIAL DUTIES AND RESPONSIBILITIES include the following: • Responsible for the design and reporting of clinical trials that meet the standards of excellence for ethics, scientific merit, and regulatory compliance, as well as satisfy corporate goals for approval of products. • Act as medical director on selected product development candidate programs. This includes designing clinical trials and an overall clinical development strategy leading to global product registration. • Interpret results of Phases 1 – 3 clinical investigations in preparation for new drug applications to relevant regulatory authorities. • Develop, draft and/or review clinical study reports and manage the presentation of key clinical findings to internal and external constituents. • Provide clinical development support for company activities and manage physician consultants and collaborators in the clinical research program. • Contribute in an active and ongoing manner to the scientific, clinical and commercial development of current and future product candidates (internally and externally developed). • Establish productive, interactive relationships with key internal departments, as well as the medical and scientific community. • Help represent the Company as needed as a senior medical spokesperson to a variety of scientific, business and government groups/agencies. • Additional duties and responsibilities that may be assigned from time to time QUALIFICATIONS To perform this job successfully, an individual must be able to perform each essential duty satisfactorily. The qualifications listed below are representative of the knowledge, skill, and/or ability required or desired. • Strategic thinking skills; able to generate ideas and opportunities and turn them into successful results. • Effective interpersonal skills: one-on-one and in groups. • Able to represent the Company in a variety of internal and external settings. • Comfortable and adept at managing an environment with rapidly changing organizational needs. • Persuasive, effective and flexible in personal interactions at all levels of the organization. • Possesses enthusiasm, credibility and commitment; is genuine and empathetic . • Entrepreneurial spirit, initiator, and generator of positive group dynamics. • A team player/builder with the ability to grow and assume greater responsibility. EXPERIENCE • Management of clinical trials (Phases 1 – 3) • Experienced in building personal collaborations, networks and teams inside and outside of the organization. EDUCATION, CERTIFICATION, LICENSES and/or REGISTRATIONS • M.D. with specialty training, preferably oncology. • 3 years experience related to the clinical development and regulatory approval of human therapeutics (drugs and/or biologics) |
» 猜你喜欢
应该是93bebmhtak前后十一个字符比较关键
已经有32人回复
2019年青年基金涵评意见,大家看看几个A,几个B?
已经有5人回复
职称评审,求友友推荐见刊最快的期刊
已经有4人回复
奇怪,两个人的filecode固定段从头到尾一模一样
已经有10人回复
综述论文作为代表作会不会影响评审专家的印象分?
已经有13人回复
是这周出结果还是下周出结果?
已经有3人回复
小木虫上这么多卖论文的,真有人买论文么?感觉没必要啊
已经有9人回复
有时候,自然基金真的不能太认真 (我的申报经验)
已经有4人回复
帮忙看看fileCode
已经有13人回复
为什么网上很多人说本周 12号出结果
已经有7人回复
» 抢金币啦!回帖就可以得到:
上海男征女 条件优秀可加微信联系
+1/452
发榜前的“心理过山车”:你经历了吗?
+5/185
国防科技大学空天科学学院招聘启事陶瓷基复合材料方向科研助理招聘
+1/97
中国科学院空天院精密干涉测量团队招聘光学/算法/机械方向博士后/特别研究助理
+1/96
威格科技:为化学合成打造全流程惰性气氛解决方案
+1/85
香港理工大学PhD/RA/PostDoc in OR/AI/OM
+1/81
新人投稿arxiv 需要cs.IT/CR大佬背书
+1/68
哈工大(深圳)何自开团队诚招2027级化学工程与技术专业博士生
+1/26
哈工大(深圳)何自开团队诚招化学工程与技术专业博士生
+1/24
中国石油大学(华东)材料科学与工程学院/新颖能源材料智能设计和开发方向 特聘副教授
+2/21
高耐腐蚀性的镁合金微弧氧化工艺
+1/11
澳门大学 应用物理及材料工程研究院 潘晖教授课题组诚招2027/2028年博士生
+1/10
关于Ghaffar-Parkins催化剂催化氰基水解为酰胺的问题
+1/9
国家级人才团队诚聘生物信息相关专业的科研助理
+1/6
【广东汕头】高校教师寻找一位志趣相投的朋友
+1/6
中山大学李国强课题组招收博士生(柔性电子方向)
+1/5
中山大学计算数学方向招2027届考核制博士生
+1/3
中国科学技术大学环境学院招聘招生
+1/2
悉尼科技大学(QS 第87)数据科学/AI招收2027年秋季入学全奖及CSC博士生
+1/1
我需要知道比open science或者claude science更牛的科研学术论文工具
+1/1
简单回复
2013-08-07 11:07
回复
neilhan(金币+5): 谢谢参与
李建广3楼
2013-08-07 13:23
回复










回复此楼